Dr. Al-Atrash is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
1515 Holcombe Blvd
Houston, TX 77030Phone+1 713-792-6161- Is this information wrong?
Education & Training
- University of Texas Health Science Center at Houston/M D Anderson Cancer CenterFellowship, Hematology and Medical Oncology, 2005 - 2008
- Cleveland Clinic FoundationResidency, Internal Medicine, 2002 - 2005
- Texas College of Osteopathic MedicineClass of 2002
Certifications & Licensure
- FL State License 2021 - Present
- AZ State License 2023 - 2026
- GA State License 2023 - 2025
- TN State License 2023 - 2025
- MS State License 2023 - 2024
- OK State License 2023 - 2024
- AL State License 2023 - 2024
- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Medical Oncology
- Join now to see all
Clinical Trials
- Nivolumab and Ipilimumab After Donor Stem Cell Transplant in Treating Patients With High Risk Refractory or Relapsed Acute Myeloid Leukemia or Myelodysplastic Syndrome Start of enrollment: 2018 Oct 11
- 2018-0674 - IL-7 for T-Cell Recovery Post Haplo and CB Transplant - Phase I/II Start of enrollment: 2020 Sep 29
Publications & Presentations
PubMed
- Identification of Nonfunctional Alternatively Spliced Isoforms of STING in Human Acute Myeloid Leukemia.Akash R Boda, Arthur J Liu, Susana Castro-Pando, Benjamin T Whitfield, Jeffrey J Molldrem, Gheath Al-Atrash, Maria Emilia Di Francesco, Philip Jones, Casey R Ager, Mic...> ;Cancer Research Communications. 2024 Mar 25
- Azacitidine Post-transplant Maintenance Improves Disease Progression in High-Risk Acute Myeloid Leukemia and Myelodysplastic Syndrome.Oren Pasvolsky, Rima M Saliba, Uday R Popat, Amin Alousi, Rohtesh Mehta, Jason Yeh, Gheath Al-Atrash, Masood Adeel, Jeremy Ramdial, David Marin, Gabriela Rondon, Parto...> ;Clinical Lymphoma, Myeloma & Leukemia. 2024 May 1
- Enhancing anti-AML activity of venetoclax by isoflavone ME-344 through suppression of OXPHOS and/or purine biosynthesis in vitro.Hurrish, K., Su, Y., Patel, S., Ramage, C., Zhao, J., Temby, B., Carter, J., Edwards, H., Buck, S., Wiley, S., Hüttemann, M., Polin, L., Kushner, J., Dzinic, S., White...> ;Biochemical Pharmacology. 2024 Feb 1
- Join now to see all
Hospital Affiliations
- University of Texas M.D. Anderson Cancer CenterHouston, Texas
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: